Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Vincent Rajkumar

Showing results (381-390 of 566) with videos related to

Pageof 57
Sort By:
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Transplantation and Cellular Therapy|April 11, 2021
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) AmyloidosisEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
British Journal of Haematology|June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
American Journal of Hematology|January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survivalCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
American Journal of Hematology|January 2, 2023
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experienceKaran L Chohan, Jonas Paludo, Nishanth Vallumsetla, et al.
Pageof 57

Showing results (381-390 of 566) with videos related to

Sort By:
Pageof 57
Leukemia & Lymphoma|July 15, 2021
Treatment and outcome of newly diagnosed multiple myeloma patients > 75 years old: a retrospective analysisAbdullah S Al Saleh, Alissa Visram, Harsh Parmar, et al.
Transplantation and Cellular Therapy|April 11, 2021
Second Stem Cell Transplantation for Relapsed Refractory Light Chain (AL) AmyloidosisEli Muchtar, Angela Dispenzieri, Shaji K Kumar, et al.
Blood Cancer Journal|July 23, 2024
Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myelomaMatthew J Rees, Aytaj Mammadzadeh, Abiola Bolarinwa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 16, 2016
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentMeletios A Dimopoulos, Pieter Sonneveld, Nelson Leung, et al.
British Journal of Haematology|June 13, 2022
Impact of belantamab mafodotin-induced ocular toxicity on outcomes of patients with advanced multiple myelomaJithma P Abeykoon, Julia Vaxman, Sanjay V Patel, et al.
American Journal of Hematology|January 2, 2023
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survivalCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Blood|August 16, 2017
Delineation of the timing of second-line therapy post-autologous stem cell transplant in patients with AL amyloidosisYi L Hwa, Rahma Warsame, Morie A Gertz, et al.
Mayo Clinic Proceedings|March 14, 2007
Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statementAngela Dispenzieri, S Vincent Rajkumar, Morie A Gertz, et al.
American Journal of Hematology|July 21, 2010
Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myelomaFrancesca Gay, S Vincent Rajkumar, Morton Coleman, et al.
American Journal of Hematology|January 2, 2023
Survival trends in young patients with Waldenström macroglobulinemia: Over five decades of experienceKaran L Chohan, Jonas Paludo, Nishanth Vallumsetla, et al.
Pageof 57